https://www.onclive.com/view/researchers-uncover-how-aggressive-breast-cancer-may-spread-to-the-brain2026-09-29T16:05:00Z2026-09-29T16:05:00Z https://www.onclive.com/view/daraxonrasib-approval-signals-a-new-era-for-ras-targeted-therapy-in-pancreatic-cancer2026-09-29T15:40:38.530Z2026-09-29T15:40:38.530Z https://www.onclive.com/view/cilta-cel-shows-long-term-treatment-free-remissions-in-lenalidomide-refractory-myeloma2026-09-29T15:30:03.089Z2026-09-29T15:30:03.089Z https://www.onclive.com/view/rusfertide-approval-expands-options-and-improves-burdens-in-polycythemia-vera2026-09-29T15:02:21.115Z2026-09-29T15:02:21.115Z https://www.onclive.com/view/savolitinib-plus-osimertinib-nda-submitted-to-fda-for-met-driven-egfr-mutated-nsclc2026-09-29T14:23:00Z2026-09-29T14:23:00Z https://www.onclive.com/view/newly-diagnosed-egfr-exon-19-deletion-nsclc-with-brain-metastases2026-09-29T12:05:00Z2026-09-29T12:05:00Z https://www.onclive.com/view/epcore-nhl-1-and-outpatient-crs-management-with-epcoritamab2026-09-29T12:05:00Z2026-09-29T12:05:00Z https://www.onclive.com/view/first-line-trastuzumab-deruxtecan-t-dxd-in-metastatic-her2-mutant-nsclc-destiny-lung04-primary-results2026-09-29T13:15:00.000Z2026-09-29T12:00:00Z https://www.onclive.com/view/destiny-breast11-in-her2-positive-early-breast-cancer2026-09-29T12:00:00Z2026-09-29T12:00:00Z https://www.onclive.com/view/framing-the-first-treatment-conversation-with-patients-and-families2026-09-29T12:00:00Z2026-09-29T12:00:00Z https://www.onclive.com/view/navigating-the-third-line-and-beyond-in-relapsed-refractory-dlbcl2026-09-29T12:00:00Z2026-09-29T12:00:00Z https://www.onclive.com/view/dr-khushman-on-the-rationale-for-investigating-inca33890-in-mss-pmmr-mcrc2026-09-28T23:33:40.034Z2026-09-28T23:33:40.034Z https://www.onclive.com/view/calculating-the-real-cost-of-false-positive-findings-in-cancer-screening2026-09-28T23:23:05.913Z2026-09-28T23:23:05.913Z https://www.onclive.com/view/dr-brown-on-the-nccn-guideline-inclusion-of-brigatinib-for-nf2-related-schwannomatosis2026-09-28T23:15:00Z2026-09-28T23:15:00Z https://www.onclive.com/view/dr-philip-on-the-mechanism-of-action-of-ttfields-in-locally-advanced-pancreatic-cancer2026-09-28T23:00:00Z2026-09-28T23:00:00Z https://www.onclive.com/view/advancing-targeted-therapy-in-hr-her2-metastatic-breast-cancer-integrating-next-generation-endocrine-and-pam-pathway-strategies-into-practice2026-09-28T21:02:27.819Z2026-09-28T21:02:27.819Z https://www.onclive.com/view/dose-intensity-anchors-jak-inhibitor-selection-as-combinations-and-targeted-agents-expand-options-in-myelofibrosis2026-09-28T20:51:27.143Z2026-09-28T20:51:27.143Z https://www.onclive.com/view/fda-grants-priority-review-to-elinzanetant-for-endocrine-therapy-associated-vasomotor-symptoms-in-hr-breast-cancer2026-09-28T20:00:00Z2026-09-28T20:00:00Z https://www.onclive.com/view/china-s-nmpa-approves-pirtobrutinib-across-cll2026-09-28T18:51:12.531Z2026-09-28T18:51:12.531Z https://www.onclive.com/view/exploring-the-fda-approval-of-optune-pax-and-what-it-means-for-locally-advanced-pancreatic-cancer2026-09-28T17:18:51.029Z2026-09-28T17:18:51.029Z https://www.onclive.com/view/roswell-park-recognizes-team-members-driving-excellence-in-cancer-care-and-research2026-09-28T16:25:00Z2026-09-28T16:25:00Z https://www.onclive.com/view/future-directions-in-multiple-myeloma-emerging-therapies-sequencing-and-the-potential-for-cure2026-09-28T12:05:00Z2026-09-28T12:05:00Z https://www.onclive.com/view/relapsed-refractory-multiple-myeloma-future-directions-in-treatment-sequencing-and-patient-outcomes2026-09-28T12:05:00Z2026-09-28T12:05:00Z https://www.onclive.com/view/expanding-community-access-to-t-cell-redirecting-therapies-in-multiple-myeloma2026-09-28T12:00:00Z2026-09-28T12:00:00Z https://www.onclive.com/view/relapsed-refractory-multiple-myeloma-best-practices-for-holding-and-bridging-therapy2026-09-28T12:00:00Z2026-09-28T12:00:00Z https://www.onclive.com/view/weighing-engineered-grafts-against-established-transplant-and-cell-therapy-approaches2026-09-28T12:00:00Z2026-09-28T12:00:00Z https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-9-202026-09-27T12:00:00Z2026-09-27T12:00:00Z https://www.onclive.com/view/iberdomide-plus-daratumumab-dexamethasone-improves-mrd-negative-cr-vs-dvd-in-relapsed-refractory-myeloma2026-09-26T15:18:00Z2026-09-26T15:18:00Z https://www.onclive.com/view/long-term-perseus-data-confirm-durable-pfs-benefit-with-d-vrd-in-transplant-eligible-newly-diagnosed-myeloma2026-09-26T15:12:00Z2026-09-26T15:12:00Z https://www.onclive.com/view/dr-voorhees-on-the-mechanism-of-action-of-etentamig-in-multiple-myeloma2026-09-26T15:07:00Z2026-09-26T15:07:00Z https://www.onclive.com/view/dr-voorhees-on-eligibility-criteria-for-the-cervino-trial-in-multiple-myeloma2026-09-26T15:01:00Z2026-09-26T15:01:00Z https://www.onclive.com/view/dr-lonial-on-the-mrd-negativity-data-from-the-excaliber-rrmm-trial-in-multiple-myeloma2026-09-26T14:57:00Z2026-09-26T14:57:00Z https://www.onclive.com/view/dr-lonial-on-the-impact-of-project-optimus-on-the-phase-3-excaliber-rrmm-trial-in-myeloma2026-09-26T14:49:00Z2026-09-26T14:49:00Z https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-9-20-20262026-09-26T12:00:00Z2026-09-26T12:00:00Z https://www.onclive.com/view/onclive-weekly-news-quiz-9-26-2026-did-you-catch-the-latest-rcc-cca-sarcoma-and-bladder-cancer-news-2026-09-26T10:00:00Z2026-09-26T10:00:00Z https://www.onclive.com/view/ifinatamab-deruxtecan-bla-voluntarily-withdrawn-in-previously-treated-extensive-stage-sclc2026-09-26T02:00:09.635Z2026-09-26T02:00:09.635Z https://www.onclive.com/view/neoadjuvant-immunotherapy-and-short-treatment-courses-drive-paradigm-shifts-in-crc-management2026-09-25T21:43:13.266Z2026-09-25T21:43:13.266Z https://www.onclive.com/view/etentamig-improves-response-and-pfs-vs-standard-therapies-in-triple-class-exposed-relapsed-refractory-myeloma2026-09-25T18:53:00Z2026-09-25T18:53:00Z https://www.onclive.com/view/fda-grants-priority-review-to-perioperative-durvalumab-plus-neoadjuvant-enfortumab-vedotin-in-mibc2026-09-25T17:59:32.123Z2026-09-25T17:59:32.123Z https://www.onclive.com/view/ai-integration-into-clinical-practice-calls-for-thoughtful-discretion-and-cautionary-measures2026-09-25T16:42:08.919Z2026-09-25T16:42:08.919Z https://www.onclive.com/view/a-new-combination-therapy-shows-promise-in-metastatic-pancreatic-cancer2026-09-25T15:15:00Z2026-09-25T15:15:00Z https://www.onclive.com/view/dr-kahl-on-future-directions-frontline-treatment-strategies-in-mcl2026-09-25T14:39:58.491Z2026-09-25T14:39:58.491Z https://www.onclive.com/view/dr-van-esser-on-the-toxicity-profile-associated-with-carfilzomib-lenalidomide-dexamethasone-in-myeloma2026-09-25T12:45:00Z2026-09-25T12:45:00Z https://www.onclive.com/view/dr-van-esser-on-long-term-follow-up-of-the-emn15-hovon147-trial-in-relapsed-refractory-myeloma2026-09-25T12:45:00Z2026-09-25T12:45:00Z https://www.onclive.com/view/brain-metastases-and-tp53-how-tumor-features-shape-frontline-intensification2026-09-25T12:05:00Z2026-09-25T12:05:00Z https://www.onclive.com/view/closing-thoughts-on-the-future-of-advanced-cutaneous-squamous-cell-carcinoma2026-09-25T12:05:00Z2026-09-25T12:05:00Z https://www.onclive.com/view/approaches-to-second-line-therapy-after-checkpoint-inhibitor-failure2026-09-25T12:00:00Z2026-09-25T12:00:00Z https://www.onclive.com/view/fda-flashback-gi-cancer-decisions-and-news-from-august-20262026-09-25T12:00:00Z2026-09-25T12:00:00Z https://www.onclive.com/view/frontline-options-in-egfr-mutant-nsclc-how-the-choice-has-gotten-more-complex2026-09-25T12:00:00Z2026-09-25T12:00:00Z https://www.onclive.com/view/dr-encinas-mayoral-on-the-advantages-of-an-ai-designed-bcma-fcrl5-targeting-trite-in-multiple-myeloma2026-09-25T03:52:00Z2026-09-25T03:52:00Z https://www.onclive.com/view/dr-encinas-mayoral-on-an-ai-designed-bcma-fcrl5-targeting-trite-in-multiple-myeloma2026-09-25T03:23:00Z2026-09-25T03:23:00Z https://www.onclive.com/view/breaking-down-the-fda-approval-of-zanidatamab-based-regimens-in-her2-gastric-cancer2026-09-24T22:57:06.950Z2026-09-24T22:57:06.950Z https://www.onclive.com/view/recent-data-readouts-help-untangle-her2-overexpression-and-mutation-implications-in-nsclc2026-09-24T21:55:00Z2026-09-24T21:55:00Z https://www.onclive.com/view/fda-approves-belzutifan-plus-lenvatinib-for-advanced-ccrcc2026-09-24T19:22:53.661Z2026-09-24T19:22:53.661Z https://www.onclive.com/view/ai-enables-enhanced-decision-making-and-new-opportunities-in-orthopedic-oncology2026-09-24T18:45:56.054Z2026-09-24T18:45:56.054Z https://www.onclive.com/view/study-shows-reprogramming-thyroid-tumors-may-improve-car-t-cell-therapy2026-09-24T16:40:00Z2026-09-24T16:40:00Z https://www.onclive.com/view/fda-mcgp-panel-vote-backs-galleri-multi-cancer-early-detection-test2026-09-24T15:43:08.076Z2026-09-24T15:43:08.076Z https://www.onclive.com/view/what-egfr-and-kras-g12c-results-tell-clinicians-beyond-treatment-selection2026-09-24T13:21:07.540Z2026-09-24T13:21:07.540Z https://www.onclive.com/view/patient-selection-and-reduced-intensity-conditioning-for-allogeneic-transplant2026-09-24T12:00:00Z2026-09-24T12:00:00Z https://www.onclive.com/view/positioning-artificial-intelligence-to-help-explain-unexpected-cancer-trial-outcomes2026-09-24T12:00:00Z2026-09-24T12:00:00Z https://www.onclive.com/view/cevostamab-plus-pomalidomide-dexamethasone-yields-durable-deep-responses-in-bcma-naive-relapsed-refractory-myeloma2026-09-24T08:54:00Z2026-09-24T08:54:00Z https://www.onclive.com/view/immagine-1-vs-cartitude-1-maic-shows-comparable-efficacy-improved-safety-with-anito-cel-in-relapsed-refractory-multiple-myeloma2026-09-24T07:55:00Z2026-09-24T07:55:00Z https://www.onclive.com/view/linvoseltamab-yields-deep-mrd-negative-responses-in-high-risk-smoldering-myeloma2026-09-24T03:58:00Z2026-09-24T03:58:00Z https://www.onclive.com/view/dr-kahl-on-frontline-strategies-for-avoiding-autologous-transplant-in-mcl2026-09-23T20:08:00Z2026-09-23T20:08:00Z https://www.onclive.com/view/fda-approves-lirafugratinib-for-pretreated-locally-advanced-or-metastatic-cholangiocarcinoma2026-09-23T20:00:22.546Z2026-09-23T20:00:22.546Z https://www.onclive.com/view/dr-kuykendall-on-the-significance-of-the-fda-approval-of-rusfertide-for-polycythemia-vera2026-09-23T19:38:13.512Z2026-09-23T19:38:13.512Z https://www.onclive.com/view/dr-mayer-on-the-fda-approval-of-camizestrant-for-esr1-mutated-breast-cancer2026-09-23T19:30:00Z2026-09-23T19:30:00Z https://www.onclive.com/view/dr-barot-on-cns-outcomes-with-palbociclib-in-her2-breast-cancer2026-09-23T19:10:00Z2026-09-23T19:10:00Z https://www.onclive.com/view/incb161734-holds-potential-significance-for-kras-g12d-mutated-mpdac-management2026-09-23T17:39:07.769Z2026-09-23T17:39:07.769Z https://www.onclive.com/view/idmc-recommends-continuation-of-phase-2-mrd-study-of-imnn-001-in-advanced-ovarian-cancer2026-09-23T16:23:34.988Z2026-09-23T16:23:34.988Z https://www.onclive.com/view/adam-trial-delivers-key-prospective-randomized-data-for-adjuvant-avelumab-in-high-risk-merkel-cell-carcinoma2026-09-23T16:09:10.594Z2026-09-23T16:09:10.594Z https://www.onclive.com/view/ucsf-breast-cancer-specialists-share-expertise-on-challenging-breast-cancer-type2026-09-23T16:00:00Z2026-09-23T16:00:00Z https://www.onclive.com/view/dr-byun-on-responses-to-mezigdomide-and-elranatamab-in-relapsed-refractory-multiple-myeloma2026-09-23T15:20:00Z2026-09-23T15:20:00Z https://www.onclive.com/view/dr-byun-on-updated-data-from-melt-mm-with-mezigdomide-and-elranatamab-in-multiple-myeloma2026-09-23T15:15:00Z2026-09-23T15:15:00Z https://www.onclive.com/view/sot106-lands-dual-fda-designations-for-osteosarcoma-and-soft-tissue-sarcoma2026-09-23T15:20:03.603Z2026-09-23T14:18:21.833Z https://www.onclive.com/view/adjuvant-avelumab-numerically-improves-rfs-in-high-risk-merkel-cell-carcinoma2026-09-23T14:00:00Z2026-09-23T14:00:00Z https://www.onclive.com/view/co-occurring-alterations-guide-treatment-choice2026-09-23T13:01:41.536Z2026-09-23T13:01:41.536Z https://www.onclive.com/view/identifying-kras-g12c-nsclc-and-ordering-testing2026-09-23T12:59:06.632Z2026-09-23T12:59:06.632Z https://www.onclive.com/view/cytoreductive-nephrectomy-in-advanced-renal-cell-carcinoma2026-09-23T12:05:00Z2026-09-23T12:05:00Z https://www.onclive.com/view/amplify-infection-rates-with-acalabrutinib-plus-venetoclax2026-09-23T12:05:00Z2026-09-23T12:05:00Z https://www.onclive.com/view/treatment-duration-in-multiple-myeloma2026-09-23T12:05:00Z2026-09-23T12:05:00Z https://www.onclive.com/view/response-depth-and-consolidative-therapy-in-advanced-renal-cell-carcinoma2026-09-23T12:00:00Z2026-09-23T12:00:00Z https://www.onclive.com/view/immune-reconstitution-after-fixed-duration-venetoclax-based-therapy2026-09-23T12:00:00Z2026-09-23T12:00:00Z https://www.onclive.com/view/anti-cd38-therapy-administration-in-multiple-myeloma2026-09-23T12:00:00Z2026-09-23T12:00:00Z https://www.onclive.com/view/fda-flashback-breast-cancer-decisions-and-news-from-august-20262026-09-22T22:17:24.200Z2026-09-22T22:17:24.200Z https://www.onclive.com/view/fda-approves-generic-lanreotide-injection-for-gep-nets2026-09-22T21:55:11.843Z2026-09-22T21:55:11.843Z https://www.onclive.com/view/fda-grants-final-approval-to-lutetium-lu-177-dotatate-biosimilar-for-sstr-gep-nets2026-09-22T21:52:35.659Z2026-09-22T21:52:35.659Z https://www.onclive.com/view/dr-anderson-on-how-to-approach-continuous-vs-fixed-duration-frontline-therapy-in-cll2026-09-22T21:44:58.168Z2026-09-22T21:44:58.168Z https://www.onclive.com/view/dr-barot-on-palbociclib-maintenance-in-hr-her2-metastatic-breast-cancer2026-09-22T21:08:00Z2026-09-22T21:08:00Z https://www.onclive.com/view/dr-kahl-on-triangle-data-and-the-changing-role-of-asct-in-frontline-mcl-management2026-09-22T20:35:00Z2026-09-22T20:35:00Z https://www.onclive.com/view/atlantic-health-centrastate-medical-center-adds-truebeam-photon-therapy-system-enhancing-advanced-cancer-care-capabilities2026-09-22T16:00:00Z2026-09-22T16:00:00Z https://www.onclive.com/view/tegavivint-plus-osimertinib-shows-early-activity-in-first-line-egfr-mutated-nsclc2026-09-22T15:20:00Z2026-09-22T15:20:00Z https://www.onclive.com/view/rusfertide-earns-category-1-nccn-status-across-polycythemia-vera-risk-groups2026-09-22T14:57:46.821Z2026-09-22T14:57:46.821Z https://www.onclive.com/view/integrating-precision-pathways-in-her2-gastroesophageal-adenocarcinoma-testing-treatment-and-supportive-care2026-09-22T14:36:24.498Z2026-09-22T14:36:24.498Z https://www.onclive.com/view/weighing-cns-activity-and-co-mutations-in-frontline-selection2026-09-22T13:17:15.866Z2026-09-22T13:17:15.866Z https://www.onclive.com/view/first-line-treatment-options-in-egfr-mutated-advanced-nsclc2026-09-22T13:09:58.182Z2026-09-22T13:09:58.182Z https://www.onclive.com/view/treatment-continuum-in-her2-positive-early-breast-cancer2026-09-22T12:58:43.658Z2026-09-22T12:58:43.658Z https://www.onclive.com/view/car-t-in-autoimmune-disease-and-key-takeaways2026-09-22T12:15:00Z2026-09-22T12:15:00Z https://www.onclive.com/view/treating-steroid-refractory-iec-ec-and-monitoring-for-complications2026-09-22T12:10:00Z2026-09-22T12:10:00Z https://www.onclive.com/view/managing-persistent-diarrhea-after-anti-bcma-car-t2026-09-22T12:05:00Z2026-09-22T12:05:00Z